CN1176099C - 天然离解素γ基因以及抗肿瘤活性多肽离解素γ - Google Patents
天然离解素γ基因以及抗肿瘤活性多肽离解素γ Download PDFInfo
- Publication number
- CN1176099C CN1176099C CNB021036799A CN02103679A CN1176099C CN 1176099 C CN1176099 C CN 1176099C CN B021036799 A CNB021036799 A CN B021036799A CN 02103679 A CN02103679 A CN 02103679A CN 1176099 C CN1176099 C CN 1176099C
- Authority
- CN
- China
- Prior art keywords
- dissociation
- essence
- gamma
- essence gamma
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000010494 dissociation reaction Methods 0.000 title claims abstract description 103
- 230000005593 dissociations Effects 0.000 title claims abstract description 102
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 11
- 101150034785 gamma gene Proteins 0.000 title claims description 5
- 230000000118 anti-neoplastic effect Effects 0.000 title claims 2
- 239000012634 fragment Substances 0.000 claims abstract description 5
- 239000002299 complementary DNA Substances 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 28
- 108090000623 proteins and genes Proteins 0.000 abstract description 26
- 150000001413 amino acids Chemical group 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 206010027476 Metastases Diseases 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 7
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 abstract description 6
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 108091036078 conserved sequence Proteins 0.000 abstract description 3
- 239000005557 antagonist Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000009401 metastasis Effects 0.000 abstract description 2
- 230000004927 fusion Effects 0.000 abstract 2
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 18
- 241000271039 Agkistrodon Species 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000008521 reorganization Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000013016 damping Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 102000012000 CXCR4 Receptors Human genes 0.000 description 10
- 108010061299 CXCR4 Receptors Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000003998 snake venom Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 239000002435 venom Substances 0.000 description 6
- 231100000611 venom Toxicity 0.000 description 6
- 210000001048 venom Anatomy 0.000 description 6
- 241001637516 Polygonia c-album Species 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000029791 ADAM Human genes 0.000 description 4
- 108091022885 ADAM Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010084455 Zeocin Proteins 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 210000001136 chorion Anatomy 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 210000001643 allantois Anatomy 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003278 egg shell Anatomy 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102100036826 Aldehyde oxidase Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241001474977 Palla Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 241000271897 Viperidae Species 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001172 blastoderm Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WQVYAWIMAWTGMW-ZLUOBGJFSA-N Ala-Asp-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WQVYAWIMAWTGMW-ZLUOBGJFSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- QKHWNPQNOHEFST-VZFHVOOUSA-N Ala-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C)N)O QKHWNPQNOHEFST-VZFHVOOUSA-N 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- OSZBYGVKAFZWKC-FXQIFTODSA-N Asn-Pro-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O OSZBYGVKAFZWKC-FXQIFTODSA-N 0.000 description 1
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 1
- GGIHYKLJUIZYGH-ZLUOBGJFSA-N Cys-Cys-Asp Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N)C(=O)O GGIHYKLJUIZYGH-ZLUOBGJFSA-N 0.000 description 1
- 241001505404 Deinagkistrodon acutus Species 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- COYGBRTZEVWZBW-XKBZYTNZSA-N Gln-Cys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(N)=O COYGBRTZEVWZBW-XKBZYTNZSA-N 0.000 description 1
- VSXBYIJUAXPAAL-WDSKDSINSA-N Gln-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O VSXBYIJUAXPAAL-WDSKDSINSA-N 0.000 description 1
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 1
- FUTAPPOITCCWTH-WHFBIAKZSA-N Gly-Asp-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FUTAPPOITCCWTH-WHFBIAKZSA-N 0.000 description 1
- HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 description 1
- 101000589010 Homo sapiens Myomesin-1 Proteins 0.000 description 1
- SJIGTGZVQGLMGG-NAKRPEOUSA-N Ile-Cys-Arg Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)O SJIGTGZVQGLMGG-NAKRPEOUSA-N 0.000 description 1
- DLFAACQHIRSQGG-CIUDSAMLSA-N Leu-Asp-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O DLFAACQHIRSQGG-CIUDSAMLSA-N 0.000 description 1
- NTBFKPBULZGXQL-KKUMJFAQSA-N Lys-Asp-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTBFKPBULZGXQL-KKUMJFAQSA-N 0.000 description 1
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 1
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 1
- 101000589013 Mus musculus Myomesin-1 Proteins 0.000 description 1
- 102100032971 Myomesin-1 Human genes 0.000 description 1
- MJAYDXWQQUOURZ-JYJNAYRXSA-N Phe-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O MJAYDXWQQUOURZ-JYJNAYRXSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- OCSACVPBMIYNJE-GUBZILKMSA-N Pro-Arg-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O OCSACVPBMIYNJE-GUBZILKMSA-N 0.000 description 1
- SHTKRJHDMNSKRM-ULQDDVLXSA-N Pro-Tyr-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O SHTKRJHDMNSKRM-ULQDDVLXSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 1
- XBWKCYFGRXKWGO-SRVKXCTJSA-N Tyr-Cys-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O XBWKCYFGRXKWGO-SRVKXCTJSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000684 melanotic effect Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000998 shell membrane Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
肿瘤体积(CM3) | 第一周 | 第二周 | 第三周 | 第四周 | 第五周 | 第六周 | 第七周 |
离解素γ组 | 0.0097±0.0012 | 0.0223±0.0054 | 0.1434±0.0134 | 0.3915±0.0752 | 0.8172±0.0932 | 1.2745±0.3127 | 1.8772±0.8432 |
PBS组 | 0.0097±0.0015 | 0.3542±0.0073 | 0.7832±0.0241 | 1.5638±0.1326 | 3.0758±0.5634 | 4.6384±0.8542 | 5.3248±1.0463 |
组别 | 动物数 | 肿瘤转移阳性率 | P值 |
离解素γ处理组 | 10 | 10%(1/10) | <0.001 |
PBS处理组 | 10 | 80%(8/10) |
组别 | 动物数 | 死亡数 | 死亡百分率 |
离解素γ组 | 10只 | 2只 | 20% |
PBS组 | 10只 | 0 | 0% |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021036799A CN1176099C (zh) | 2002-02-08 | 2002-02-08 | 天然离解素γ基因以及抗肿瘤活性多肽离解素γ |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021036799A CN1176099C (zh) | 2002-02-08 | 2002-02-08 | 天然离解素γ基因以及抗肿瘤活性多肽离解素γ |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1374318A CN1374318A (zh) | 2002-10-16 |
CN1176099C true CN1176099C (zh) | 2004-11-17 |
Family
ID=4739861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021036799A Expired - Fee Related CN1176099C (zh) | 2002-02-08 | 2002-02-08 | 天然离解素γ基因以及抗肿瘤活性多肽离解素γ |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1176099C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110426522B (zh) * | 2019-08-13 | 2021-01-12 | 上海赛伦生物技术股份有限公司 | 一种圆斑蝰蛇蛇毒的鉴定方法及其应用 |
-
2002
- 2002-02-08 CN CNB021036799A patent/CN1176099C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1374318A (zh) | 2002-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101812438B (zh) | 一种精氨酸脱亚氨酶突变体及其制备与应用 | |
CN105899217A (zh) | 癌症疗法中的番木瓜花叶病毒和病毒样颗粒 | |
CN108484747B (zh) | 倭蛙皮肤修复肽cathelicidin-NV及其基因和应用 | |
CN105531284A (zh) | 细胞穿透肽和包含其的缀合物 | |
CN101062952B (zh) | 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用 | |
CN108834417A (zh) | 具有抗炎症活性的肽及其用途 | |
CN1106846C (zh) | 抗癌症剂 | |
CN102973922A (zh) | 一种融合蛋白的应用 | |
WO2017067510A1 (zh) | 一种多肽及其在制备治疗和预防肿瘤的药物中的应用 | |
CN104031135A (zh) | 树蛙防御肽PopuDef及其基因和应用 | |
CN1176099C (zh) | 天然离解素γ基因以及抗肿瘤活性多肽离解素γ | |
CN1824775A (zh) | 重组人血管抑素k1-3的制备工艺及其制品在肿瘤治疗药物中的应用 | |
CN105884876B (zh) | 一种蚯蚓多肽、其编码序列及其应用 | |
CN101671390B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
CN100398557C (zh) | 血管生成抑制多肽及其制备方法和应用 | |
CN106496329B (zh) | 一种含有胶原蛋白结合结构域的融合蛋白 | |
CN102516382B (zh) | 一种海南湍蛙抗微生物肽Hainanenin-5及其基因、应用 | |
CN107446024A (zh) | 一种可拮抗ddx3蛋白rna结合活性的多肽dip‑13及其应用 | |
CN1294258C (zh) | 一种分离抗菌肽的方法与分离的抗菌肽 | |
CN101015683B (zh) | 人rtn4b蛋白在制备创伤愈合药物中的应用 | |
CN101096384A (zh) | 一种抗肿瘤融合蛋白的制备方法及其应用 | |
CN104356216A (zh) | 版纳绳蚋防御肽SibaDef及其基因和应用 | |
CN1232532C (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN103096916A (zh) | 用于牛粒细胞集落刺激因子及其变体的制剂 | |
CN100335499C (zh) | C端氨基酸内酯修饰型胸腺素α1及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
C10 | Entry into substantive examination | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU MORUIKE BIOTECHNOLOGY CO., LTD Free format text: FORMER OWNER: MI JUN Effective date: 20100309 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100088 LOGISTICS ENGINEERING CENTER, MINISTRY OF COMMUNICATIONS HIGHWAY RESEARCH INSTITUTE, NO.8, XITUCHENG ROAD, HAIDIAN DISTRICT, BEIJING CITY TO: 215011 ROOM 407, SUZHOU BIOMEDICAL CENTER, NO.1326, BINHE ROAD, SUZHOU CITY |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100309 Address after: 215011 Suzhou biological medicine center, room 407, Binhe Road, Suzhou, 1326 Patentee after: Suzhou silent sharp gram biotechnology Ltd Address before: 100088 Beijing city Haidian District Xitucheng road science No. 8 Highway Logistics Engineering Center Patentee before: Mi Jun |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041117 Termination date: 20120208 |